AZN.UK

12,586

+0.74%↑

GSK

1,622

-1.85%↓

HLN.UK

331.8

+0.36%↑

STJ

1,291

+1.1%↑

AZN.UK

12,586

+0.74%↑

GSK

1,622

-1.85%↓

HLN.UK

331.8

+0.36%↑

STJ

1,291

+1.1%↑

AZN.UK

12,586

+0.74%↑

GSK

1,622

-1.85%↓

HLN.UK

331.8

+0.36%↑

STJ

1,291

+1.1%↑

AZN.UK

12,586

+0.74%↑

GSK

1,622

-1.85%↓

HLN.UK

331.8

+0.36%↑

STJ

1,291

+1.1%↑

AZN.UK

12,586

+0.74%↑

GSK

1,622

-1.85%↓

HLN.UK

331.8

+0.36%↑

STJ

1,291

+1.1%↑

Search

Hikma Pharmaceuticals PLC

Closed

SectorHealthcare

1,841 1.43

Overview

Share price change

24h

Current

Min

1800

Max

1856

Key metrics

By Trading Economics

Income

133M

Sales

100M

1.7B

P/E

Sector Avg

13.384

35.739

EPS

1.07

Dividend yield

5.06

Profit margin

8.537

Employees

9,500

EBITDA

-29M

259M

Recommendations

By TipRanks

Recommendations

Strong Buy

12 Months Forecast

+37.72% upside

Dividends

By Dow Jones

Dividend yield

Sector Avg

5.06%

3.08%

Market Stats

By TradingEconomics

Market Cap

-1.4B

3.7B

Previous open

1839.57

Previous close

1841

News Sentiment

By Acuity

41%

59%

120 / 371 Healthcare

Hikma Pharmaceuticals PLC Chart

Past performance is not a reliable indicator of future results.

Related News

1 Oct 2025, 08:54 UTC

Major Market Movers

Pharma Stocks in Europe Jump After White House Unveils Drug-Buying Site

8 Apr 2025, 08:20 UTC

Market Talk

Med-Tech Investors Seek 'Safe Havens' Amid Tariff Fears -- Market Talk

Peer Comparison

Price change

Hikma Pharmaceuticals PLC Forecast

Price Target

By TipRanks

37.72% upside

12 Months Forecast

Average 2,472 GBX  37.72%

High 2,850 GBX

Low 1,982 GBX

Based on 6 Wall Street analysts offering 12 month price targets forHikma Pharmaceuticals PLC - Dist in the last 3 months.

Rating Consensus

By TipRanks

Strong Buy

6 ratings

5

Buy

1

Hold

0

Sell

Sentiment

By Acuity

120 / 371 Healthcare

News Sentiment

Bullish Evidence

Volatility

Below average

News Volume (RCV)

Below average

Financials

Selling and administration expenses

Operating expenses

Pre-tax profit

Sales

Cost of sales

Gross profit on sales

Interest expense on debt

EBITDA

Operating profit

$

About Hikma Pharmaceuticals PLC

Hikma Pharmaceuticals PLC develops, manufactures, markets, and sells a range of generic, branded, and in-licensed pharmaceutical products. It operates through three segments: Injectables, Generics, and Branded. The Injectables segment provides generic injectable products primarily for use in hospitals. The Generics segment offers oral and other non-injectable generic products for the retail market. The Branded segment offers branded generics and in-licensed products to retail and hospital markets. The company provides its products in various therapeutic areas, including respiratory, oncology, and pain management. It also offers its products in solid, semi-solid, liquid, and injectable final dosage forms. The company operates in the United Kingdom, rest of Europe, North America, the Middle East, North Africa, and internationally. Hikma Pharmaceuticals PLC was founded in 1978 and is headquartered in London, the United Kingdom.
help-icon Live chat